Eikon Therapeutics, Inc. (EIKN)
NasdaqGS · USD · Healthcare · Biotechnology
$5.54 (-23.69%) as of
Key statistics
- Market cap
- 300.07M
- Forward P/E
- -0.83
- EPS (TTM)
- -8.51
- Dividend yield
- 0.00%
- 52-week range
- 5.44 – 17.40
- Profit margin
- 0.00%
- Analyst target
- $24.33
- Volume
- 965.18k
About Eikon Therapeutics, Inc.
Eikon Therapeutics, Inc., operates as a clinical biopharmaceutical company in the United States. It develops medicines to address serious unmet medical needs. Its products include EIK1001, a systemically administered TLR 7/8 dual-agonist designed to activate innate and adaptive immune anti-tumor responses; EIK1003 and EIK1004, which are selective PARP1 inhibitors in ovarian, breast, prostate, and pancreatic cancers and, specifically with the brain-penetrant; EIK1004 to address brain metastases and primary brain malignancies; EIK1005, a potent WRN helicase inhibitor and anti-tumor agent for MSI-high tumors; and EIK1006, a clinical candidate and next-generation androgen receptor antagonist with activity against multiple clinically emergent variants of androgen receptor. The company was incorporated in 2019 and is based in Millbrae, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Millbrae, CA, United States
- Employees
- 384
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.